The demand for animal alternatives such as human organoids, bioprinted human tissue constructs, and organ-on-chips is immense. These alternatives are essential for improving the prediction of drug candidate toxicity and efficacy, thereby enhancing the success rate of screening new compounds during preclinical evaluations.

Due to the FDA Modernization Act 2.0, passed in December 2022, there is an enormous need for animal alternatives such as human organoids, bioprinted human tissue constructs, and organ-on-chips to better predict the toxicity and efficacy of new drug candidates and increase the success rate of compound screening in preclinical evaluations. BPL addresses critical customer needs in this market by combining the three alternative models into one pillar/perfusion plate platform. Recently, great advances have been made in organotypic 3D cell/tissue models, such as human organoids, for disease modeling. However, human organoid cultures have been performed on low-throughput platforms such as 6/24-well plates, petri dishes, and spinner flasks, which significantly limit their use in preclinical evaluations. BPL has targeted this bottleneck by developing innovative, microarray 3D bioprinting of human organoids in the pillar/perfusion plate and facilitating robust organoid culture and imaging in situ for predictive compound screening.